BOTOX ®

(Botulinum toxin, Type A)

Actual patient. Treatment results may vary.

BOTOX® Botulinum toxin type-A is a prescription only medicine that should only be given by physicians with appropriate qualifications, and expertise in the treatment and the use of the required equipment.

BOTOX® is approved in 98 countries worldwide1* and in several therapeutics and aesthetics indications.2

For aesthetics indications BOTOX is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows (glabellar lines) seen at maximum frown and/or moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile and/or moderate to severe forehead lines seen at maximum eyebrow elevation when the severity of the facial lines has an important psychological impact in adult patients.2

For full list of approved indications, please refer to the Summary of Product Characteristics

Product Status: Prescription Medicine
Active Ingredient:
Botulinum toxin type-A


For Patients

Product Information:

Package Information Leaflet

Bahrain

Kingdom of Saudi Arabia

Kuwait

Oman

Qatar

United Arab Emirates

Report a Side Effect or Adverse Event

PV.MEA@abbvie.com


For Providers

Product Information:

Summary of Product Characteristics

Bahrain

Kingdom of Saudi Arabia

Kuwait

Oman

Qatar

United Arab Emirates

Provider Product Scientific Questions

From Gulf countries

From Kingdom of Saudi Arabia

1 Allergan. Unpublished Data. INT-BCT-2050129. Worldwide BOTOX® marketing authorisation as of 2020. October 2020.
* Therapeutic and aesthetic use.
2 SmPC-BOTOX-100